Hybrid peptide DNA nanomaterials enable potent and broad-spectrum virus neutralization
Umrao, S.; Dwivedy, A.; Haak, P. L.; Gandavadi, D.; Rund, L.; Chen, C.; Zhou, L.; Duan, J.; Fang, Y.; Steelman, A.; Wang, X.
Show abstract
The continued emergence of antigenic drift and drug-resistant viral strains highlights the need for antiviral strategies that deliver robust efficacy, broad subtype coverage, and minimal off-target toxicity. We demonstrate a potent and broad-spectrum strategy that employs hybrid biomaterials of Urumin (a host defense peptide) and a honeycomb (HC) DNA origami through spatially organized multivalent presentation for enhanced antiviral efficacy. Molecular dynamics simulations reveal that Urumin penetrates and destabilizes the hemagglutinin (HA) trimer core, disrupting influenza A viral (IAV) entry. Arranging Urumin in trimeric clusters on the HC enables potent multivalent binding to trimeric HAs on IAV, enhancing antiviral efficacy at nanomolar concentrations, [~]1,000-fold more effective than free Urumin. In vitro assays confirm HC-Urumin outperforms free Urumin in blocking viral entry and preserving cell viability in more IAV subtypes. In vivo studies show that compared to free Urumin, HC-Urumin treatment reduces disease severity, preserves physiological behavior, and decreases mortality in infected mice, while maintaining virus-specific adaptive immune responses without altering humoral immunity. Our study offers an advanced and effective materials platform and strategy for broad-spectrum, low-dose intervention against human and animal IAVs, which can be adapted to combat other viruses by patterning corresponding host defense peptides on custom designed DNA nanostructures.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Non-Toxic Virucidal Macromolecules Show High Efficacy Against Influenza Virus Ex Vivo and In Vivo 97%
- Sustained vaccine exposure elicits more rapid, consistent, and broad humoral immune responses to multivalent influenza vaccines 94%
- Trypstatin as a Novel TMPRSS2 Inhibitor with Broad-Spectrum 1 Efficacy Against Corona and Influenza Viruses 92%
Similar papers in this journal
- Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates 94%
- Glycan remodeled erythrocytes facilitate antigenic characterizationof recent A/H3N2 influenza viruses 94%
- Glycan-induced structural activation softens the human papillomavirus capsid for entry through reduction of intercapsomere flexibility 94%
Similar papers in this journal
- Engineering protease-resistant peptides to inhibit human parainfluenza viral respiratory infection 95%
- Identification of Covalent Cyclic Peptide Inhibitors Targeting Protein-Protein Interactions Using Phage Display 93%
- An RNA to rule them all: Critical steps in Lassa virus ribonucleoparticle assembly and recruitment 92%
Similar papers in this journal
- A modular self-assembling and self-adjuvanting multiepitope peptide nanoparticle vaccine platform to improve the efficacy and immunogenicity of BCG 93%
- Effects of DNA Origami-Based Nanoagent Design on Apoptosis Induction in a Large 3D Spheroid Model 92%
- Artificial immune cell, AI-cell, a new tool to predict interferon production by peripheral blood monocytes in response to nucleic acid nanoparticles 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.